Loading
SLC6A2 (Sodium-dependent noradrenaline transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signalling neurotransmitter in the autonomic sympathetic nervous system. Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis. Can also mediate sodium- and chloride-dependent transport of dopamine.
Open Targets scores its association with cancer at 0.53 (direct and indirect evidence; datatypes literature 0.23, genetic association 0.00, clinical 0.86).
In plain words · SLC6A2 (Sodium-dependent noradrenaline transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
SLC6A2 (Sodium-dependent noradrenaline transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signalling neurotransmitter in the autonomic sympathetic nervous system.
No product in this corpus aims at SLC6A2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SLC6A2: RNA tissue enhanced (adrenal gland 10 nTPM, placenta 6 nTPM, skin 1 4 nTPM); high antibody staining in 3 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours); Open Targets associates it with 3 specific cancer types at or above 0.5 (paraganglioma, adrenal gland pheochromocytoma, pheochromocytoma); the corpus evidence decides and the Open Targets list is quoted for comparison. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SLC6A2 tissue; Open Targets ENSG00000103546 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Pacholczyk et al, Nature, 1991, "Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter". Source.
Sources: HGNC HGNC:11048 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23975 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000103546 (association with cancer (MONDO_0004992) 0.53; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.58 (GraphQL API, CC0))
Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signalling neurotransmitter in the autonomic sympathetic nervous system. Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis. Can also mediate sodium- and chloride-dependent transport of dopamine. Location: Cell membrane; Cell projection, axon; Synapse, synaptosome (UniProt). Locus 16q12.2 (HGNC).
RNA: tissue enhanced (adrenal gland 10 nTPM, placenta 6 nTPM, skin 1 4 nTPM, testis 4 nTPM), detected in some normal tissues.
Medium: Soft tissue.
RNA cancer enhanced: Liver Hepatocellular Carcinoma 6 pTPM.
No cancer stained high; medium in breast cancer, colorectal cancer, endometrial cancer, prostate cancer.
HPA SLC6A2 tissue · HPA SLC6A2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SLC6A2" OR ABSTRACT:"SLC6A2" OR TITLE:"solute carrier family 6 member 2" OR ABSTRACT:"solute carrier family 6 member 2" OR TITLE:"Sodium-dependent noradrenaline transporter" OR ABSTRACT:"Sodium-dependent noradrenaline transporter" OR TITLE:"NET1" OR ABSTRACT:"NET1" OR TITLE:"NAT1" OR ABSTRACT:"NAT1" OR TITLE:"SLC6A5" OR ABSTRACT:"SLC6A5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SLC6A2, not a curated reading list.